Cart
sales@molnova.com
Mebhydroline
CAS No. 524-81-2
Mebhydroline( —— )
Catalog No. M18727 CAS No. 524-81-2
Mebhydrolin is a specific histamine H1 receptor antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 33 | In Stock |
|
| 200MG | 53 | In Stock |
|
| 500MG | 115 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMebhydroline
-
NoteResearch use only, not for human use.
-
Brief DescriptionMebhydrolin is a specific histamine H1 receptor antagonist.
-
DescriptionMebhydrolin is a specific histamine H1 receptor antagonist.(In Vitro):Mebhydrolin is a specific histamine H1-receptor antagonist and comparing it with the effects of chlorpromazine, the archetypical phenothiazine. Mebhydrolin exerts an antihistaminic effect over the period of the ethanol interaction study.
-
In VitroMebhydrolin is a specific histamine H1-receptor antagonist and comparing it with the effects of chlorpromazine, the archetypical phenothiazine. Mebhydrolin exerts an antihistaminic effect over the period of the ethanol interaction study.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorH1 receptor
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number524-81-2
-
Formula Weight276.38
-
Molecular FormulaC19H20N2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 83.33 mg/mL 301.51 mM
-
SMILESCN3Cc4c1ccccc1n(Cc2ccccc2)c4CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.O'Neill PA,etal.Chlorpromazine--a specific effect on breathlessness Br J Clin Pharmacol. 1985 Jun;19(6):793-7.
molnova catalog
related products
-
Bak BH3
This peptide, generated from the BH3 domain of Bak (Flu-BakBH3), has been shown to have high-affinity binding to a surface pocket of the Bcl-XL protein that is required for its death antagonist function.
-
Phytone
Phytone enhanced both the sticky materials production and cell growth ?plays some role in the increase of sticky materials and cell growth.
-
Ruplizumab
Ruplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease .
